Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Gram-Negative Infections Due to Multidrug-Resistant Enterobacteriaceae | Decision Base | US | 2014
As Healthcare Providers Seek to Contain Growing Costs, New Agents Will Need to Demonstrate Improvements Across Efficacy, Safety, and Delivery Attributes to Justify Premium Pricing The increasing…
Venous Thromboembolism (U.S. Uptake of the Novel Oral Anticoagulants in Venous Thromboembolism: Impact of Physicians and Payers on Prescribing?) | Physician & Payer Forum | US | 2014
Venous thromboembolism (VTE) is a potentially fatal cardiovascular condition characterized by the development of a thrombus in the vasculature. Treatment options for VTE have been largely limited…
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Relapsed/Refractory) | Decision Base | US/EU | 2014
As the Relapsed/Refractory Treatment Setting for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Becomes More Crowded, What Key Attributes Will Differentiate Emerging Therapies According to…
A New Era for Multiple Sclerosis Disease-Modifying Therapy: EU5 Prescriber and Payer Perspectives on Current Mainstays, Recent Market Entrants, and Late-Stage Pipeline Products | Physician & Payer Forum | EU5 | 2014
By February 2014, European marketing authorizations were granted for three new disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS)—Aubagio (Sanofi/Genzyme), Lemtrada (…
Hospital-Treated Infections (Access to Novel Antibiotics: How Are Payers and Physicians Shaping the Market?) | Physician & Payer Forum | China | 2014
The lackluster global antibiotics pipeline and surge of antibiotic resistance in clinical isolates in China have triggered a new quest for novel antibiotics against complicated HTI. Many local and…
